Literature DB >> 9837691

Enhancement of immune complex clearance by TNF-alpha in a murine model.

M F Alves-Rosa1, M S Palermo, M A Isturiz.   

Abstract

Recently, we presented evidence that lipopolysaccharide (LPS) treatment of BALB/c mice induces an enhancement on mononuclear phagocytic system functions, leading to a more efficient clearance of immune complexes (IC). In the present study we analyzed the role of tumor necrosis factor alpha (TNF-alpha), one of the earliest mediators released after LPS injection, in the clearance of IC. Our results show that the enhancing effect of LPS on clearance can be partially reproduced by intravenous injection of sera from mice injected with LPS 1 h before. At this time point, the levels of TNF-alpha reach a maximal peak of 240 +/- 73 U50%/ml [TNF-alpha (+) serum]. However, sera obtained after 4 h of LPS injection, with a TNF-alpha activity of 3.5 U50%/ml [TNF-alpha (-) serum], did not exert any relevant effect on IC clearance. In addition, the effect of TNF-alpha (+) serum was completely blocked by preincubation with rabbit anti-TNF-alpha antibody. Moreover, the enhancement of IC clearance can be similarly induced by administering murine recombinant TNF-alpha. Furthermore, the LPS-insensitive C3H/HeJ mice, which do not secrete TNF-alpha in response to LPS, showed a normal IC clearance after LPS injection. Taken together, these results strongly suggest that the enhancement of IC clearance by LPS treatment could be mediated, at least in part, by TNF-alpha. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837691     DOI: 10.1006/clin.1998.4610

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

2.  Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Authors:  James B Galloway; Kimme L Hyrich; Louise K Mercer; William G Dixon; Bo Fu; Andrew P Ustianowski; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580

3.  Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis.

Authors:  M Benucci; G Saviola; P Baiardi; M Manfredi; P Sarzi Puttini; Fabiola Atzeni
Journal:  Open Rheumatol J       Date:  2012-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.